|
Business |
|
Gujarat Themis Biosyn (GUJTHEM), incorporated in 1981, is engaged in manufacturing active pharmaceutical ingredients. It was taken over by Pharmaceutical Business Group India, a consortium of five pharma firms - Themis Chemicals, Kopran, Anant & Co, Cadila and Lyka Labs. In technical and financial collaboration with Yuhan of South Korea, the company started production of anti-tuberculosis drug, Rifampicin.... More.. |
|
Future Plans |
|
|
|
|
One To One
|
|
Recent news
|
|
|
| Brief Financials (in Rs. Mn.) | |
| Period ending (months) | 31-Mar-2016(12) | 31-Mar-2015(12) | 31-Mar-2014 (12) | | Net sales | 326.25 | 314.40 | 302.30 | | Other Income | 1.08 | 0.88 | 1.60 | | Total Income | 327.33 | 315.28 | 303.90 | | Cost of goods sold | 267.81 | 251.70 | 236.86 | | OPBDIT | 59.52 | 63.58 | 67.04 | | PAT | 46.81 | 45.95 | 45.26 | | Gross Block | - | - | - | | Equity capital | 72.64 | 72.64 | 72.64 | | EPS (Rs.) | - | - | 3.12 | | DPS (Rs.) | - | - | - | | BV (Rs.) | - | - | - | | P/E range (x) | - | - | 2.39 - 4.55 | | Debt / Equity (x) | - | - | - | | Operating margin (% of OI) | 18.2 | 20.2 | 22.1 | | Net margin (% of OI) | 14.3 | 14.6 | 14.9 |
|
|
Detailed Financials
|
|
|
|
|
